{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T01:14:58Z","timestamp":1789953298283,"version":"4.0.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.jaip.2018.04.007","type":"journal-article","created":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T12:58:48Z","timestamp":1523624328000},"page":"2065-2072.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders"],"prefix":"10.1016","volume":"6","author":[{"given":"Francesca","family":"Nencini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Vultaggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Pratesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Cammelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Milla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginevra","family":"Fiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siro","family":"Bagnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Prignano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Romagnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Matucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2018.04.007_bib1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.trsl.2014.09.006","article-title":"Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases","volume":"165","author":"Willrich","year":"2015","journal-title":"Transl Res"},{"key":"10.1016\/j.jaip.2018.04.007_bib2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3899\/jrheum.091464","article-title":"Optimizing use of tumor necrosis factor inhibitors in the management of immune-mediated inflammatory diseases","volume":"85","author":"Bressler","year":"2010","journal-title":"J\u00a0Rheumatol Suppl"},{"key":"10.1016\/j.jaip.2018.04.007_bib3","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.2165\/00003495-200565150-00014","article-title":"Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis","volume":"65","author":"Siddiqui","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.jaip.2018.04.007_bib4","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/nrrheum.2013.4","article-title":"Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis","volume":"9","author":"Van Schouwenburg","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jaip.2018.04.007_bib5","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/art.23447","article-title":"Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab","volume":"58","author":"Mitoma","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaip.2018.04.007_bib6","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2018.04.007_bib7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/annrheumdis-2014-206237","article-title":"The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region","volume":"74","author":"Van Schie","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaip.2018.04.007_bib8","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/j.1572-0241.2007.01638.x","article-title":"Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease","volume":"103","author":"Ainsworth","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaip.2018.04.007_bib9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ajg.2012.363","article-title":"Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis","volume":"108","author":"Nanda","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaip.2018.04.007_bib10","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/ibd.21831","article-title":"Therapeutic drug monitoring of biologics for inflammatory bowel disease","volume":"18","author":"Colombel","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jaip.2018.04.007_bib11","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cyto.2008.11.008","article-title":"Differences in binding and effector functions between classes of TNF antagonists","volume":"45","author":"Arora","year":"2009","journal-title":"Cytokine"},{"key":"10.1016\/j.jaip.2018.04.007_bib12","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","article-title":"Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents","volume":"49","author":"Horiuchi","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaip.2018.04.007_bib13","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/cea.12098","article-title":"Allergological in\u00a0vitro and in\u00a0vivo evaluation of patients with hypersensitivity reactions to infliximab","volume":"43","author":"Matucci","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2018.04.007_bib14","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1398-9995.2009.02280.x","article-title":"Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions","volume":"65","author":"Vultaggio","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2018.04.007_bib15","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/gutjnl-2013-305259","article-title":"The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab","volume":"63","author":"Bella Ungar","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.jaip.2018.04.007_bib16","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2018.04.007_bib17","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/ibd.20520","article-title":"Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis","volume":"14","author":"Lewis","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jaip.2018.04.007_bib18","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A\u00a0simple index of Crohn's disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2018.04.007_bib19","first-page":"S93","article-title":"The Disease Activity Score and the EULAR response criteria","volume":"23","author":"Fransen","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaip.2018.04.007_bib20","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/ard.62.9.817","article-title":"International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis","volume":"62","author":"Braun","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaip.2018.04.007_bib21","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the Birmingham Vasculitis Activity Score (version 3)","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaip.2018.04.007_bib22","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/rheumatology\/ker124","article-title":"Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis","volume":"50","author":"Pascual-Salcedo","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaip.2018.04.007_bib23","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1136\/annrheumdis-2011-201270","article-title":"Anti-TNF treatment blocks the induction of T cell-dependent humoral responses","volume":"72","author":"Salinas","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaip.2018.04.007_bib24","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.clim.2014.02.008","article-title":"Inhibition of TNF receptor signaling by anti-TNF\u03b1 biologicals primes na\u00efve CD4(+) T cells towards IL-10(+) T cells with a regulatory phenotype and function","volume":"151","author":"Boks","year":"2014","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.007_bib25","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.4049\/jimmunol.1700008","article-title":"IL-10\u2013producing infliximab-specific T cells regulate the antidrug T cell response in exposed patients","volume":"199","author":"Vultaggio","year":"2017","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaip.2018.04.007_bib26","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S1542-3565(04)00238-1","article-title":"Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease","volume":"2","author":"Hanauer","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jaip.2018.04.007_bib27","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/gast.2003.50145","article-title":"Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial","volume":"124","author":"Farrell","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaip.2018.04.007_bib28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","article-title":"The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients","volume":"126","author":"Colombel","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaip.2018.04.007_bib29","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2036.2011.04682.x","article-title":"Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease","volume":"34","author":"Steenholdt","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jaip.2018.04.007_bib30","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1136\/ard.2006.065615","article-title":"Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis","volume":"66","author":"Bartelds","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaip.2018.04.007_bib31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3899\/jrheum.140685","article-title":"Prevalence of TNF-\u03b1 blocker immunogenicity in psoriatic arthritis","volume":"42","author":"Zisapel","year":"2015","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.jaip.2018.04.007_bib32","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.3748\/wjg.v21.i6.1907","article-title":"Significance of low level infliximab in the absence of anti-infliximab antibodies","volume":"21","author":"Ungar","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jaip.2018.04.007_bib33","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/rheumatology\/kem261","article-title":"Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies","volume":"46","author":"Svenson","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaip.2018.04.007_bib34","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/ibd.22910","article-title":"Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease","volume":"18","author":"Steenholdt","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jaip.2018.04.007_bib35","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.clinthera.2010.07.021","volume":"32","author":"Stubenrauch","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaip.2018.04.007_bib36","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa074943","article-title":"Cetuximab-induced anaphylaxis and IgE specific for galactosealpha-1,3-galactose","volume":"358","author":"Chung","year":"2008","journal-title":"N\u00a0Engl Med"},{"key":"10.1016\/j.jaip.2018.04.007_bib37","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000336839","article-title":"Drug-specific Th2 cells and IgE antibodies in a patient with anaphylaxis to rituximab","volume":"159","author":"Vultaggio","year":"2012","journal-title":"Int Arch Allergy Immunol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219818302782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219818302782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:16:21Z","timestamp":1761974181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219818302782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S2213219818302782"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2018.04.007","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2018.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}